Using 17 α-hydroxyprogesterone caproate to impact rates of recurrent preterm delivery in clinical practice

Andrei Rebarber, Nathan S. Fox, Chad K. Klauser, Niki B. Istwan, Debbie J. Rhea, Gary J. Stanziano, Daniel H. Saltzman

Research output: Contribution to journalArticlepeer-review

9 Scopus citations

Abstract

Objective.Evaluation of an outpatient 17 α-hydroxyprogesterone caproate (17P) administration programme. Methods.A retrospective analysis of data collected from patients with a history of preterm birth (PTB) and current singleton gestation enrolled between 16.0 and 20.9 weeks' gestational age (GA) for weekly outpatient 17P administration and nursing assessment between 7/2004 and 12/2007 was conducted (n3139). Results.The population was mostly white (50.3), 1835 years old (77.7), and married (67.0). Median GA at 17P initiation and stop was 17.4 (16.0, 20.9) weeks and 35.1 (18.6, 37.4) weeks. Mean injections per patient were 16.5±4.9, at an interval of 7.2 days. Median GA at delivery was 37.3 (18.6, 44.0) weeks. Rate of recurrent spontaneous PTB was 29.8, with 15.5 and 7.0 with PTB at<35 and<32 weeks. Conclusions.This represents the largest cohort reported to date of patients prescribed 17P therapy in clinical practice to prevent recurrent spontaneous PTB.

Original languageEnglish
Pages (from-to)1139-1142
Number of pages4
JournalJournal of Maternal-Fetal and Neonatal Medicine
Volume23
Issue number10
DOIs
StatePublished - Oct 2010
Externally publishedYes

Keywords

  • 17 α-hydroxyprogesterone caproate
  • preterm birth prevention
  • progesterone

Fingerprint

Dive into the research topics of 'Using 17 α-hydroxyprogesterone caproate to impact rates of recurrent preterm delivery in clinical practice'. Together they form a unique fingerprint.

Cite this